KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Cash (2016 - 2025)

Historic Change in Cash for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $166.0 million.

  • Alnylam Pharmaceuticals' Change in Cash rose 22402.69% to $166.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $690.2 million, marking a year-over-year increase of 34882.88%. This contributed to the annual value of $690.2 million for FY2025, which is 34882.88% up from last year.
  • Alnylam Pharmaceuticals' Change in Cash amounted to $166.0 million in Q4 2025, which was up 22402.69% from $376.9 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Change in Cash high stood at $497.7 million for Q3 2022, and its period low was -$285.9 million during Q1 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Change in Cash averaged around $58.0 million, with its median value being $47.5 million (2022).
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Change in Cash plummeted by 24926818.18% in 2021, and later soared by 208457.91% in 2024.
  • Alnylam Pharmaceuticals' Change in Cash (Quarter) stood at -$274.3 million in 2021, then rose by 24.6% to -$206.8 million in 2022, then dropped by 6.52% to -$220.3 million in 2023, then soared by 39.25% to -$133.8 million in 2024, then skyrocketed by 224.03% to $166.0 million in 2025.
  • Its Change in Cash stands at $166.0 million for Q4 2025, versus $376.9 million for Q3 2025 and $93.6 million for Q2 2025.